Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
Feasibility award granted by Technology Strategy Board to identify DUBs.

MISSION Therapeutics has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.

Ovarian cancer is the fifth most common cancer in women and is responsible for more deaths per year than any other cancer of the female reproductive system.

Unfortunately, development of drug resistance remains the main limitation of current chemotherapies for ovarian cancer.

Identifying novel targets and therapies tailored for treating drug-resistant ovarian cancer is thus an area of clear unmet clinical need.

Using an innovative approach, MISSION will identify novel DUB targets by exploiting the very changes in tumours that led to the development of drug resistance.

Commenting on the announcement, Dr Niall Martin, MISSION Chief Operating Officer, said: “The decision of the Technology Strategy Board to support our work shows the potential the DUB space holds for treating cancer. The funds from this Feasibility Award will be used to screen all known DUBs to find those which are suitable targets for our drug development programmes.”

The project will see MISSION identify DUB targets whose inhibition selectively kills drug-resistant ovarian tumours or re-sensitizes them to chemotherapy.

The most promising targets will enter MISSION’s pipeline for further drug discovery efforts with a view to developing new therapeutic agents for ovarian cancer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
MISSION Therapeutics Strengthens Board
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.
Monday, October 01, 2012
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!